MedTrace Logo

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

NCT07447817 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-03-18

No results posted yet for this study

Summary

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Conditions

  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG

Pacritinib

Pacritinib 200mg twice a day (BID) by mouth (PO)

DRUG

Selinexor

Selinexor 60mg once weekly (QW) by mouth (PO)

Sponsors & Collaborators

  • Sobi, Inc.

    collaborator INDUSTRY

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • John Mascarenhas

    lead OTHER

Principal Investigators

  • John Mascarenhas, MD · Icahn School of Medicine at Mount Sinai

  • Abdulraheem Yacoub, MD · University of Kansas School of Medicine

  • Ruben Mesa, MD, FACP · Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-04
Primary Completion
2030-05-24
Completion
2030-05-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07447817 on ClinicalTrials.gov